paediatric oncology

Oncology

Now set to be acquired by Servier for $2.5 billion, Day One Bio proves how far a mission-driven biotech with a strong team and good timing can go.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.